000752019 000__ 05364cam\a2200505Ii\4500
000752019 001__ 752019
000752019 005__ 20230306141351.0
000752019 006__ m\\\\\o\\d\\\\\\\\
000752019 007__ cr\cn\nnnunnun
000752019 008__ 150930s2016\\\\ja\\\\\\ob\\\\000\0\eng\d
000752019 019__ $$a922917801$$a931592858$$a932333581
000752019 020__ $$a9784431555827$$q(electronic book)
000752019 020__ $$a443155582X$$q(electronic book)
000752019 020__ $$z9784431555810
000752019 020__ $$z4431555811
000752019 0247_ $$a10.1007/978-4-431-55582-7$$2doi
000752019 035__ $$aSP(OCoLC)ocn922581492
000752019 035__ $$aSP(OCoLC)922581492$$z(OCoLC)922917801$$z(OCoLC)931592858$$z(OCoLC)932333581
000752019 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dN$T$$dIDEBK$$dOCLCF$$dYDXCP$$dEBLCP$$dNUI$$dCOO$$dGW5XE
000752019 049__ $$aISEA
000752019 050_4 $$aRC776.F5
000752019 08204 $$a616.2/4$$223
000752019 24500 $$aIdiopathic pulmonary fibrosis$$h[electronic resource] :$$badvances in diagnostic tools and disease management /$$cHiroyuki Nakamura and Kazutetsu Aoshiba, editors.
000752019 264_1 $$aTokyo :$$bSpringer,$$c[2016]
000752019 264_4 $$c©2016
000752019 300__ $$a1 online resource.
000752019 336__ $$atext$$btxt$$2rdacontent
000752019 337__ $$acomputer$$bc$$2rdamedia
000752019 338__ $$aonline resource$$bcr$$2rdacarrier
000752019 504__ $$aIncludes bibliographical references.
000752019 5050_ $$aPreface; References; Contents; Part I: Definition, Epidemiology, and Pathogenesis; Chapter 1: Definition of IPF; 1.1 Introduction; 1.2 The ATS/ERS/JRS/ALAT 2011 Revised Diagnostic Criteria [5]; 1.3 Clinical Application and Key Problems; 1.4 Conclusion; References; Chapter 2: Epidemiology and Risk Factors of IPF; 2.1 Introduction; 2.2 Incidence and Prevalence; 2.2.1 In the USA; 2.2.2 In Europe; 2.2.3 In Japan; 2.3 Potential Risk Factors; 2.3.1 Smoking; 2.3.2 Inhalational Exposures; 2.3.3 Viral Infection; 2.3.4 Herpesviruses; 2.3.5 Hepatitis C Virus; 2.3.6 Gastroesophageal Reflux
000752019 5058_ $$a2.3.7 Diabetes Mellitus2.4 Genetic Factors; 2.4.1 Familial Interstitial Pneumonia (FIP); 2.4.2 ELMOD2; 2.4.3 Surfactant Protein; 2.4.4 Telomerase; 2.4.5 MUC5B; 2.5 Conclusions; References; Chapter 3: Acute Exacerbation of IPF; 3.1 Introduction; 3.2 Definition; 3.3 Pathophysiology; 3.4 Trigger Factors; 3.5 Epidemiology; 3.6 Histopathology; 3.7 Radiological Assessment; 3.8 Laboratory Tests and Biomarkers; 3.9 Pharmacological Treatments; 3.10 Therapy with Polymyxin B-Immobilized Fiber Column; 3.11 Prevention; 3.12 Conclusions; References; Chapter 4: Pathogenesis of IPF
000752019 5058_ $$a4.1 Hypothesis of the Molecular Pathogenesis of IPF: From Inflammation to Epithelial Injury4.2 Epithelial Injury and Genetic Background; 4.3 Biological Alteration in Injured AEC in IPF; 4.4 Critical Roles of Growth Factors in the Progression of Pulmonary Fibrosis; 4.4.1 PDGF and PDGF Receptors; 4.4.2 FGF and FGF Receptors; 4.4.3 VEGF and VEGF Receptors; 4.4.4 TGF-beta and TGF-beta Receptors; 4.4.5 Origin of Lung Fibroblasts and Their Contribution to Pulmonary Fibrosis; 4.4.6 Loss of Alveolar Epithelial Integrity and Pulmonary Fibrosis; 4.4.7 Resolution of ECM and Fibrosis; 4.4.8 Conclusions
000752019 5058_ $$a5.7 Relation Between HRCT Findings and Biomarkers5.8 Mechanism and Significance for Dissociation Among Serum Biomarker Levels; 5.9 Biomarkers for IPF Other Than SP-A, SP-D, and KL-6; 5.10 Conclusion; References; Chapter 6: High-Resolution Computed Tomography of Honeycombing and IPF/UIP; 6.1 Introduction; 6.2 Honeycomb Lung (Honeycombing); 6.2.1 Definition of Honeycomb Lung; 6.2.2 Disagreement Among Radiologists in Judging Honeycomb Lung; 6.3 Imaging Findings of Idiopathic Pulmonary Fibrosis/Usual Interstitial Pneumonia; 6.3.1 Pathologic Criteria of IPF/UIP; 6.3.2 HRCT Criteria of IPF/UIP
000752019 506__ $$aAccess limited to authorized users.
000752019 520__ $$aFrom epidemiology and pathogenesis to disease management, this book reviews our current understanding of and provides up-to-date information of Idiopathic Pulmonary Fibrosis (IPF). A subtype of Idiopathic Interstitial Pneumonias (IIP), IPF is one of the most elusive and intractable respiratory disease to date and its triggering factors remain unclear. However, new developments such as serum markers that are highly specific to IPF (i.e. KL-6, SP-A, and SP-D), the establishment of systematic diagnostic imaging (HRCT) and accumulated reports of treatment using an antifibrotic agent (pirfenidone) are slowly improving our understanding of the disease. Edited by an established authority in the field and written by experts, this book will be valuable to not only to beginning learners but also to physicians, instructors and researchers whose work involves IIPs. With each chapter exploring critical questions, with unresolved issues and future prospects, the book offers a valuable resource for understanding issues such as the newly proposed entity of interstitial pneumonia with emphysema (combined pulmonary fibrosis and emphysema: CPFE) and the mechanism of how so many IIP sufferers develop lung cancer.
000752019 588__ $$aOnline resource; title from PDF title page (viewed October 2,  2015).
000752019 650_0 $$aPulmonary fibrosis.
000752019 7001_ $$aNakamura, Hiroyuki,$$eeditor.
000752019 7001_ $$aAoshiba, Kazutetsu,$$eeditor.
000752019 77608 $$iPrint version:$$z9784431555810$$z4431555811$$w(OCoLC)911068522
000752019 852__ $$bebk
000752019 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-4-431-55582-7$$zOnline Access$$91397441.1
000752019 909CO $$ooai:library.usi.edu:752019$$pGLOBAL_SET
000752019 980__ $$aEBOOK
000752019 980__ $$aBIB
000752019 982__ $$aEbook
000752019 983__ $$aOnline
000752019 994__ $$a92$$bISE